Detailed explanation of the mechanism of action and clinical application of cimepilimab

Cemiplimab (cemiplimab-rwlc), as an innovative programmed death receptor-1 (PD-1) blocking antibody (also known as an immune checkpoint inhibitor), has achieved remarkable results in the field of cancer immunotherapy in recent years. This article will provide a detailed analysis of the mechanism of action of cimepilimab and its wide range of uses in clinical applications.

First, let’s understand the mechanism of action of cimepilimab. Immune checkpoints are an important part of the immune system, preventing healthy cells from being destroyed when a strong immune response is triggered in the body. However, cancer cells sometimes use this mechanism to evade immune system attack. When a protein on the surface of a T cell recognizes and binds to a chaperone protein on a cancer cell, it sends a "shutdown" signal to the T cell, preventing the immune system from destroying the cancer cell. Cimepilimab, as a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody, inhibits binding to cancer cell proteins by blocking PD-1. This means that T cells can remain active and continue to attack and kill cancer cells.

In clinical applications, cimepilimab has shown a wide range of uses. It is used to treat patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, particularly those who are not candidates for curative surgery or radiation therapy. Additionally, cimepilimab is an effective treatment option for patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) who have been previously treated with a hedgehog pathway inhibitor or if this treatment is not suitable for them. In addition, cimepilimab is also used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. These patients typically do not have EGFR, ALK, or ROS1 abnormalities or may be treated with platinum-based chemotherapy. Cimepilimab can also be used as a single agent in patients whose tumors have high PD-L1 expression.

In summary, cimepilimab plays an important role in the field of cancer immunotherapy through its unique mechanism of action. It has demonstrated significant therapeutic effects in multiple cancer types, bringing new treatment options and hope to patients. It is reported that cimipilimab is currently only available and sold in overseas markets. In the European market, one box is priced at more than 40,000 yuan.